3.8 Review

microRNAs: New-Age Panacea in Cancer Therapeutics

期刊

INDIAN JOURNAL OF SURGICAL ONCOLOGY
卷 12, 期 SUPPL 1, 页码 52-56

出版社

SPRINGER INDIA
DOI: 10.1007/s13193-020-01110-w

关键词

MiRNA; Dysregulation; Cancer; Clinical trial

类别

资金

  1. DBT [BT/PR10272/BRB/10/1266/2013, BT/PR8670/AGR/36/757/2013, DBT/2017/IISc/828]
  2. DST-FIST [SR/FST/LS11-036/2014(C)]
  3. UGC-SAP [F.4.13/2018/DRSIII (SAP-II)]
  4. DBT-IISc Partnership Program Phase-II [BT/PR27952INF/22/212/2018]

向作者/读者索取更多资源

MiRNAs are small non-coding RNAs that play a crucial role in regulating gene expression. Dysregulated expression of miRNAs in human cancers can affect tumor development through various mechanisms.
MicroRNAs (miRNAs) are small (similar to 18-25 nucleotides in length), endogenous, non-coding RNAs, which regulate gene expression. Numerous studies have demonstrated the dysregulation of miRNA expression in human cancers through various mechanisms, which include genetic alteration of miRNA genes, abnormal transcriptional control of miRNAs, anomalous epigenetic changes, and defective miRNA biogenesis machinery. They may function as either oncomiRs or tumor suppressor miRNAs in a tissue or cell-specific manner. The dysregulated miRNAs are known to affect the hallmarks of cancer, and some of these miRNAs have shown therapeutic promise in pre-clinical and clinical studies. Here, we briefly touch upon various aspects of miRNA biology with a particular focus on their roles in cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据